SEC 13F Intelligence

Commodore Capital LP / PTGX

Commodore Capital LP’s Protagonist Therapeutics Inc Position

Does Commodore Capital LP own Protagonist Therapeutics Inc (PTGX)? Not currently — the last reported position was 450.0K shares worth $39M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$39M
Q4 2025
Shares
450.0K
% of Portfolio
+2.62%
Quarters Held
9
position exited

Position History PTGX

Reported value by quarter
Q4 ’20: $7MQ4 ’20Q1 ’21: $9MQ2 ’21: $9MQ2 ’21Q3 ’21: $9MQ4 ’21: $28MQ4 ’21Q1 ’22: $8MQ2 ’25: $59MQ2 ’25Q3 ’25: $68MQ4 ’25: $39MQ4 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q4 2025450.0K$39M+2.62%
Q3 20251.02M$68M+3.32%
Q2 20251.07M$59M+4.19%
Q1 2022331.9K$8M+1.76%
Q4 2021805.6K$28M+6.38%
Q3 2021498.1K$9M+2.33%
Q2 2021210.6K$9M+3.26%
Q1 2021349.6K$9M+3.56%
Q4 2020347.5K$7M+3.81%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Commodore Capital LP’s full portfolio or all institutional holders of PTGX.